Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free adipose tissue in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8 post infection followed by cyclophosphamide induced immunosuppression on day 80 post infection measured after day 100 post infection by PCR method relative to control
Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free adipose tissue in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 70 post infection followed by cyclophosphamide induced immunosuppression on day 80 post infection measured after day 100 post infection by PCR method relative to control
Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes assessed as decrease in serum alkaline phosphatase level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 70 post infection measured on day 100 post infection relative to control
Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasitemia reactivation in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 70 post infection followed by cyclophosphamide induced immunosuppression on day 80 post infection by Neubauer chamber relative to control
Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasitemia reactivation in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8 post infection followed by cyclophosphamide induced immunosuppression on day 80 post infection by Neubauer chamber relative to control
Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes infected in BALB/c mouse assessed as reduction in serum Ig-G level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8 post infection and measured at day 14 post infection by ELISA
Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigote assessed as effect on parasite glycolytic pathway by measuring decrease in succinate excretion at IC50 after 72 hrs by H NMR method relative to control
Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes infected in BALB/c mouse assessed as reduction in serum Ig-G level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 70 post infection measured at day 76 post infection by ELISA
Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum uric acid level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8 post infection and measured on day 100 post infection by biochemical analysis relative to control
Genotoxicity in Salmonella typhimurium TA1535 harboring pSK1002 assessed as survival at 0.5 mg/ml in absence of Sprague-Dawley rat liver S9 fraction metabolic activation by SOS/umu assay relative to control
Genotoxicity in Salmonella typhimurium TA1535 harboring pSK1002 assessed as umu gene induction at 0.008 mg/ml in presence of Sprague-Dawley rat liver S9 fraction metabolic activation by SOS/umu assay relative to control